pipamperone has been researched along with Depressive Disorder, Major in 1 studies
pipamperone: RN given refers to parent cpd; structure
pipamperone : A member of the class of bipiperidines that is 1,4'-bipiperidine which is substituted at the 1' and 4' positions by 4-(p-fluorophenyl)-4-oxobutyl and carboxamide groups, respectively. A first generation antipsychotic, its properties are generally similar to those of haloperidol.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pipamperone acts as a highly selective 5-HT2A/D4 antagonist when administered in low doses." | 2.76 | Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. ( Buntinx, E; Crawford, GM; Haazen, L; McConnachie, A; Nemeroff, CB; Schatzberg, AF; Schlaepfer, T; Wade, AG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wade, AG | 1 |
| Crawford, GM | 1 |
| Nemeroff, CB | 1 |
| Schatzberg, AF | 1 |
| Schlaepfer, T | 1 |
| McConnachie, A | 1 |
| Haazen, L | 1 |
| Buntinx, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD)[NCT00672659] | Phase 2 | 165 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pipamperone and Depressive Disorder, Major
| Article | Year |
|---|---|
Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
Topics: Adolescent; Adult; Aged; Butyrophenones; Citalopram; Depressive Disorder, Major; Double-Blind Method | 2011 |